EMA Authorised: Thiotepa Riemser (thiotepa) — Esteve Pharmaceuticals GmbH

View source ↗

Summary

EMA authorised Thiotepa Riemser for indications related to hematopoietic stem cell transplantation and neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematopoietic Stem Cell Transplantation-related Conditions
• Neoplasms

Drugs mentioned

• Thiotepa Riemser (thiotepa)

Snippet

Status: Authorised. Therapeutic area: Hematopoietic Stem Cell Transplantation;Neoplasms. MAH: Esteve Pharmaceuticals GmbH. Decision date: 18/10/2023